Abstract 3434
Background
Liposarcoma (LPS) is one of the most common types of soft tissue sarcoma (STS), including four subtypes: well-differentiated/atypical lipomatous tumor (ALT/WDLPS), dedifferentiated liposarcoma (DDLPS), myxoid/round cell liposarcoma (MLPS/RCLPS) and pleomorphic liposarcoma (PLS). The morphological diversity of LPS reflects the heterogeneity in clinical and biological behavior and sensitivity to chemotherapy.
Methods
The study involved six patients affected by low/high grade LPS (1 ALT/WDLPS and DDLPS, 1 DDLPS, 2 MLPS, 1 RCLPS and 1 PLS). Patient-derived primary cultures were established after patient surgery. The cultures were exposed to drugs currently used (e.i. ifosfamide, epirubicin, trabectidin, eribulin) for the treatment of LPS. Drug concentrations were selected according to the human plasma peak in patients with solid tumors. Percentages of cellular survival were assessed by MMT and TUNEL assays.
Results
The results showed the sensitivity of the cultures to chemotherapy. The combination of ifosfamide and epirubicin was the most active regimen and statistically significant among cultures. Ifosfamide did not affect the survival of the cells, except in RCLPS suggesting its role in this LPS subtype. Epirubicin showed a comparable activity of the combination regimen in DDLPS (28%) and RCLPS (14%) while displayed a lesser cytotoxic effect in ALT/WDLPS and DDLPS (83%) and MLPS (65%). Trabectidin had no effect on the cellular survival in DDLPS and an equivalent activity in ALT/WDLPS and DDLPS and MPLS (61% and 65% respectively). In RCLPS exhibited an important activity (28%). Trabectidin showed a higher efficacy in ALT/WDLPS and DDLPS and a similar trend in MLPS compared to epirubicin. Eribulin displayed a comparable activity of trabectidin in ALT/WDLPS and DDLPS (70%), MLPS (68%) and RCLPS (26%) while was more active in DDLPS (83%). Finally, cellular survival of PLS was not affected by all the drugs.
Conclusions
This study provides a rationale for elucidate the role of chemotherapy for all liposarcoma subtypes using patient-derived LPS primary cultures. The improvement in the understanding of the molecular mechanisms in liposarcoma will help in selecting the appropriate treatment with a potential impact in the clinical setting.
Clinical trial identification
Legal entity responsible for the study
Toni Ibrahim.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4742 - Ki67 as an important predictor for Oncotype Dx Recurrence score risk groups in Early Breast cancer
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4697 - Genetic signatures always suggest undertreatment? Experience with PAM51
Presenter: Carolina Sales
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3158 - Significance of receptors expression, mitotic index and Ki67 in breast cancer patients with Nottingham Prognostic Index (NPI) poor prognosis score
Presenter: Mejri Nesrine
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3838 - Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients
Presenter: Javier Cortes Castan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
715 - Autoimmunity and benefit from trastuzumab treatment in breast cancer: results from the HERA phase 3 trial
Presenter: Amir Sonnenblick
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2388 - Impact of hormone receptor status in HER2+ early breast cancer: a paradigm shift in the trastuzumab era
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3742 - Sefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The french HERMIONE non-interventional prospective study
Presenter: jean-philippe Jacquin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3647 - Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer.
Presenter: Rita De Sanctis
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3837 - Comprehensive evaluation of the pharmacokinetic profiles of SB3 and reference trastuzumab
Presenter: Xavier Pivot
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1692 - The impact of neoadjuvant dual HER2 targeting with Pertuzumab and Trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience
Presenter: Samantha Forner
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract